Member Info for Lurker2020

The penny seems to finally be dropping, so there's definitely 3-4 exciting months ahead like many have said. Ever since Activ2 progression was announced, I've decided I'm not selling anything until at least £8. Why? We've had one great bit of news, sure, but look at the price we're at already and the fireworks haven't begun to go off.

I'm just going to write this here for my own jollies, as I need an outlet for my brimming excitement - but speculation from others is welcome as well. With no particular date order, I'd like to see;

1) First patient dosed Activ2 P3
2) TR1 accumulating
3) P3 Recruitment complete
4) Maybe another TR1
5) P3 results
6) Pre-order
7) T/O or further orders

And the snowball gains even greater momentum! I'm trying to not get too carried away here (as per usual) but I think things are going to get very crazy, very quickly - the evidence is stacking up.

I'm assuming that the data will be really good, and whilst it may not result in the same percentage gain to the SP as the P2 results, I believe that getting approval and EUA is as inevitable as a takeover ultimately - then again, I'm very bullish on SNG purely because it's still the supposedly most efficacious treatment out there to date, and P3 will confirm that.

I still think £5-10 is easily achieveable by the endgame, at least, my target price is in that range.

Have a good weekend all.

Matterhorn and Woodstock,

Maybe I am getting a little ahead of myself, but it's certainly been a frustrating journey as an investor here - no gains have ever sustained themselves over the last 12 months, this seems to be the level in which it plateaus after good and bad news.

I just hope that, despite what the institutions say, their interests align somewhat with ours when it comes down to the crunch, and that it's not a way for a buyer to get in with a low-ball offer.

The sad thing about this is that whoever ends up taking over Synairgen (which I believe is an inevitability), they're going to get it for a song unless PI's get their act together and start holding onto shares, rather than trading for a pittance of profit all the time (RM said this in the panel discussion this week in a round-about way)

For a company that's on the brink of announcing P3 results, with a world-class drug and what I hope to be a successful transition in the Activ2 trial to name it's near-future prospects - I think the SP is a disgrace, and doesn't reflect it's true value.

Synairgen will have it's day, and very soon too.

I'm not sure what's more annoying as an investor here; that there's overwhelming support for the greatness of this product, and it should've been given EUA months ago and given the recognition it deserves?
Or that other treatments that show a faction of the efficacy of SNG001 hog the limelight?

At the end of the day, more people have died from some form of viral lung infection (covid, copd, asthma etc.) that needn't have, and that's the worst thing.

Jfc, it really beggars belief the amount of people who pay so much attention to prolific derampers/idiots.

Just filter them and grow up!

A little bit unrelated now, but this is what I believe will happen over the next 3-4 months and act as catalysts for positive SP movement;

1) Activ2 Progression to P3
2) Final patient dosed RNS (presentation: november)
3) P3 trial data (presentation: January)
4) EUA/Government support/orders

It doesn't really matter what happens between now and January-ish, as I believe the SP will be at least £3 on P3 results day ????????

Stu, I'd imagine that production will start at the end of this year and into 2022 and beyond.

The treatment has a shelf-life of 5 years in deep freeze, so your question doesn't make any real sense to me?

For what I know, I'd say it's because history has shown us that whenever big pharma talk, the masses listen - albeit to their own detriment further down the line. Governments around the world like the word 'cheap', so if someone comes along with the next 'wonder drug' that can be bought on the cheap, it'll get bought regardless of it's efficacy or even safety. Between that point, and big pharma having the cash to grease the right wheels, you can see why they're able to stop a trial early and push this new crud out.

You watch, people will be kicking off about this molnupiravir in several months time after it starts getting dished out, and it's continued efficacy and safety will be brought into question only after several million people have taken it. Remdesivir and Ivermectin come to mind straight away.

Ayyy, all the derampers are back! That's got to be a good sign ;)

I'm not sure whether it's already been mentioned, but maybe this whole analyst thing could be to review long covid data? I know the company were looking into that, but I'm not sure when that data might be ready.

It depends on the definition of 'significant progression' to be honest.

I'd say there's at least 2 events, hopefully within the next 3 months, that'll serve as catalysts for the SP - Activ2 news and P3 results. There could of course be other things such as pre-orders at any time, or regular orders after P3 news drops.

Either way, I'm excited for what the future holds and don't think the SP will languish at this level for too much longer.

I'd also like to thank the people who've sold out, and allowed me to get another bunch of shares at a nice discount this morning. News is so close I can taste it, and I look forward to the months ahead!

And the point of this is what, exactly?
More frequent posters on this board will recognise that a large majority of those names (if not all, I mean, I don't live on here) are excellent researchers who contribute a great deal to this board, but if sharing great research into a stock now makes you a ramper then yeah, I guess they are.

My mistake Kevin, once it got into abusive territory I did skim past the conversation and went on the original topic headline and your first message. You're right in that sense though, it doesn't take much for insults to start flying and it's usually unnecessary - this bb can be like a coiled spring a lot of the time.

Remember the last time people were begging for an RNS and the company seemingly obliged and released one shortly after? Remember the effect that had on the share price? If the answer is "yes" to both of those questions, you'll do like the majority of us are doing and wait patiently if you've done your DD on this stock.

Ever since Friday's RNS regarding Polygon doubling their stake, it's given me the final bit of confidence (not that I needed that much more confidence anyway) that this is a good thing to be involved in. 17.9% of Synairgen's share capital is now with institutions, I'm not entirely sure about total director shareholding percentage, but it goes to show that the big money people are feathering their nests for the events to come.

LTH's are just waiting patiently for that blistering RNS to eventually land, as always.
Welcome to any newbies that have acquired shares recently :D